Adalimumab
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Adalimumab: TNF-α inhibitor → hypermobility of coccyx
One-Sentence Summary
Adalimumab is a TNF-α-blocking biologic that is currently marketed in Canada, including as several biosimilar products. The TxGNN model predicts it may be relevant to hypermobility of coccyx, but this is a computational prediction only. No clinical trials and no publications directly support it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypermobility of coccyx |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Adalimumab is a monoclonal antibody that blocks tumour necrosis factor-α (TNF-α), a key driver of inflammation in immune-mediated diseases. Detailed mechanism-of-action data were not available in the data compiled for this report. The description here reflects the drug’s known class.
The high TxGNN score is a model-derived signal and is not supported by biological or clinical evidence. Hypermobility of the coccyx is largely a mechanical or traumatic condition, and no clear TNF-driven inflammatory pathway links it to adalimumab. The similarity to the drug’s established uses has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Adalimumab is marketed in Canada under several brand names, including the reference product and biosimilars. The records compiled for this report may be partial. Indication text and dosage forms were not recorded in the local data.
| DIN | Product Name |
|---|---|
| 02258595 | HUMIRA |
| 02458349 | HUMIRA |
| 02511061 | ABRILADA |
| 02542331 | HYRIMOZ |
| 02459310 | AMGEVITA |
Safety Considerations
Drug Interactions (100 interactions were recorded; the first 20 are summarised below):
- Major:
- Systemic corticosteroids: betamethasone, budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, triamcinolone (including ophthalmic)
- Deferiprone
- Radiopharmaceuticals: ibritumomab tiuxetan, iobenguane (I-131), tositumomab and tositumomab (I-131)
- Moderate: metronidazole, tinidazole, rosuvastatin, simvastatin
- Minor: zinc acetate, zinc gluconate, zinc sulfate
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No trials or publications address this condition, and no plausible TNF-mediated mechanism has been identified. Evidence is at the lowest level (L5).
To proceed, the following is needed:
- A clear pathophysiological rationale showing that TNF-α-driven inflammation contributes to the condition
- Any clinical or preclinical studies in this condition (case series, observational data or mechanistic studies)
- Detailed mechanism-of-action data and the Health Canada package insert warnings and contraindications
- A safety assessment against the recorded major interactions, particularly with corticosteroids
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.